Yükleniyor... / Loading...
This study examines how chicory-derived inulin-type β-fructans, by modulating the gut microbiota, affect the gut-skin axis in people with psoriasis. It enrolled people with mild psoriasis (PASI < 10) who were in generally good health. It was a study with no assigned phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria for PS patients: * mild psoriasis (PASI \< 10), * omnivorous diet, * body mass index (BMI) 18 - 30 kg/m2 * general good health * willing to give the written informed consent to participate the study Exclusion Criteria for PS patients: * other chronic or acute inflammatory skin diseases, * gastrointestinal disease, cancer, cardiovascular complications, heart, kidney, and liver failure, * bad or average overall health, * positive tTG antibodies, * currently receive anti-psoriatic systemic and biologic treatment, * received antibiotics within previous month, * use of dietary supplements containing probiotic, prebiotic, and/or symbiotic within previous month, * Pregnancy, lactation